Health ❯ Healthcare ❯ Diabetes ❯ Type 2 Diabetes

Treatment Options

Lancet Phase 3 Trial Shows Oral GLP-1 Orforglipron Aids Weight Loss and Diabetes Control

Lilly aims to seek approval with a potential 2026 rollout, positioning the once‑daily tablet as a more accessible alternative to injections.

Lilly’s Orforglipron Pill Hits Phase 3 Goals and Outperforms Oral Semaglutide in Diabetes Study

Eli Lilly to Raise UK Mounjaro Prices by Up to 170% in September

JAMA Studies Find Rare Optic-Nerve Risks With Semaglutide and Tirzepatide

GLP-1 Weight-Loss Drugs Linked to Testosterone Normalization in Men

Novo Nordisk’s Amycretin Achieves Up to 24% Weight Loss as It Advances to Phase 3